A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...

A large Mayo Clinic study shows that current guidelines fail to detect nearly 90% of people with familial hypercholesterolemia, a common inherited cause of dangerously high cholesterol. Many affected ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

Natera, Inc. , a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Early findings from the FANSS study, presented at ESMO Asia 2025, point to a potential shift in how clinicians identify lung ...

The treatment success rate for cancer patients improves when doctors detect the disease during its initial stages, because ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...